Edition:
United Kingdom

Deciphera Pharmaceuticals Inc (DCPH.OQ)

DCPH.OQ on NASDAQ Stock Exchange Global Select Market

24.74USD
8:12pm BST
Change (% chg)

$0.27 (+1.10%)
Prev Close
$24.47
Open
$24.90
Day's High
$25.79
Day's Low
$24.63
Volume
29,069
Avg. Vol
61,045
52-wk High
$45.12
52-wk Low
$18.56

Latest Key Developments (Source: Significant Developments)

Deciphera Pharma And Zai Lab Ltd Announce Exclusive License Agreement For Ripretinib In Greater China
Tuesday, 11 Jun 2019 

June 11 (Reuters) - Deciphera Pharmaceuticals Inc ::DECIPHERA PHARMACEUTICALS, INC. AND ZAI LAB LIMITED ANNOUNCE AN EXCLUSIVE LICENSE AGREEMENT FOR RIPRETINIB IN GREATER CHINA.DECIPHERA PHARMACEUTICALS INC - ZAI LAB TO LEAD DEVELOPMENT AND COMMERCIALIZATION OF RIPRETINIB IN GREATER CHINA.DECIPHERA PHARMACEUTICALS INC - TO RECEIVE $20 MILLION UPFRONT CASH PAYMENT, UP TO $185 MILLION IN POTENTIAL FUTURE MILESTONES AND ROYALTIES.DECIPHERA PHARMACEUTICALS INC - INTENDS TO EXPAND RIPRETINIB DEVELOPMENT PROGRAM IN GASTROINTESTINAL STROMAL TUMORS.DECIPHERA PHARMACEUTICALS INC - WILL BE ELIGIBLE TO RECEIVE UP TO $185 MILLION IN POTENTIAL DEVELOPMENT AND COMMERCIAL MILESTONE PAYMENTS.  Full Article

Deciphera Pharma Reports Q1 Loss Per Share Of $1.25
Thursday, 9 May 2019 

May 9 (Reuters) - Deciphera Pharmaceuticals Inc ::DECIPHERA PHARMACEUTICALS, INC. ANNOUNCES FIRST QUARTER 2019 FINANCIAL RESULTS.Q1 LOSS PER SHARE $1.25.Q1 EARNINGS PER SHARE ESTIMATE $-0.84 -- REFINITIV IBES DATA.ENDED Q1 2019 WITH CASH, CASH EQUIVALENTS AND MARKETABLE SECURITIES OF $262 MILLION.  Full Article

Deciphera Pharmaceuticals Initiates Phase 3 Study Of Ripretinib (Dcc-2618)
Thursday, 20 Dec 2018 

Dec 20 (Reuters) - Deciphera Pharmaceuticals Inc ::DECIPHERA PHARMACEUTICALS INITIATES PIVOTAL PHASE 3 CLINICAL STUDY OF RIPRETINIB (DCC-2618) IN SECOND-LINE PATIENTS WITH GASTROINTESTINAL STROMAL TUMORS (“INTRIGUE” STUDY).DECIPHERA - EXPECT TO REPORT TOP-LINE DATA FROM FIRST PHASE 3 CLINICAL STUDY, INVICTUS, IN FOURTH-LINE AND FOURTH-LINE-PLUS GIST PATIENTS IN MID-2019.  Full Article

Deciphera Pharmaceuticals Announces Closing Of Public Offering Of Common Stock
Monday, 11 Jun 2018 

Deciphera Pharmaceuticals Inc ::DECIPHERA PHARMACEUTICALS ANNOUNCES CLOSING OF PUBLIC OFFERING OF COMMON STOCK.  Full Article

Deciphera Pharmaceuticals Q4 Loss Per Share $0.62
Wednesday, 28 Mar 2018 

March 28 (Reuters) - Deciphera Pharmaceuticals Inc ::DECIPHERA PHARMACEUTICALS, INC. ANNOUNCES FOURTH QUARTER 2017 FINANCIAL RESULTS AND CORPORATE HIGHLIGHTS.Q4 LOSS PER SHARE $0.62.Q4 EARNINGS PER SHARE VIEW $-0.46 -- THOMSON REUTERS I/B/E/S.  Full Article

Deciphera Pharmaceuticals Q3 loss $5.85 per share​
Tuesday, 14 Nov 2017 

Nov 14 (Reuters) - Deciphera Pharmaceuticals Inc : :Deciphera Pharmaceuticals Inc announces third quarter 2017 financial results and corporate highlights.Qtrly loss $5.85 per share​.Q3 earnings per share view $-0.61 -- Thomson Reuters I/B/E/S.  Full Article

New Leaf Venture reports 12.9 pct stake in Deciphera Pharmaceuticals
Wednesday, 11 Oct 2017 

Oct 11 (Reuters) - Deciphera Pharmaceuticals Llc :New Leaf Venture Management III LLC reports 12.9 percent stake in Deciphera Pharmaceuticals as of Oct 2 - SEC filing‍​.  Full Article

Viking Global Investors reports 8.1 pct passive stake in Deciphera Pharmaceuticals
Wednesday, 11 Oct 2017 

Oct 11 (Reuters) - Deciphera Pharmaceuticals Llc :Viking Global Investors LP reports 8.1 percent passive stake in Deciphera Pharmaceuticals LLC ‍​as of Oct 2 - SEC filing‍​.  Full Article

Deciphera Pharmaceuticals shares open 17.9 pct above IPO price in debut
Thursday, 28 Sep 2017 

Sept 28 (Reuters) - :Deciphera Pharmaceuticals shares open at $20.05 in debut on NASDAQ vs IPO price of $17 per share.  Full Article